Innoviva Price to Free Cash Flow Ratio 2010-2024 | INVA

Historical price to free cash flow ratio values for Innoviva (INVA) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Innoviva Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2025-01-31 18.64 17.28
2024-09-30 19.31 $1.08 17.90
2024-06-30 16.40 $1.01 16.28
2023-12-31 16.04 $1.62 9.91
2023-09-30 12.99 $2.93 4.44
2023-06-30 12.73 $3.09 4.12
2023-03-31 11.25 $2.56 4.39
2022-12-31 13.25 $3.08 4.30
2024-03-31 15.24 $2.45 6.22
2022-09-30 11.61 $2.62 4.43
2022-06-30 14.76 $4.03 3.66
2022-03-31 19.35 $4.16 4.65
2021-12-31 17.25 $3.86 4.47
2021-09-30 16.71 $4.00 4.18
2021-06-30 13.41 $3.08 4.35
2021-03-31 11.95 $2.85 4.19
2020-12-31 12.39 $2.76 4.49
2020-09-30 10.45 $2.60 4.03
2020-06-30 13.98 $2.45 5.72
2020-03-31 11.76 $2.24 5.25
2019-12-31 14.16 $2.27 6.24
2019-09-30 10.54 $2.22 4.74
2019-06-30 14.56 $2.25 6.47
2019-03-31 14.03 $2.21 6.36
2018-12-31 17.45 $1.97 8.85
2018-09-30 15.24 $1.83 8.35
2018-06-30 13.80 $1.66 8.31
2018-03-31 16.67 $1.39 11.98
2017-12-31 14.19 $1.18 12.00
2017-09-30 14.12 $0.95 14.84
2017-06-30 12.80 $0.75 17.01
2017-03-31 13.83 $0.66 20.98
2016-12-31 10.70 $0.49 21.72
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.183B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.326B 79.06
Novo Nordisk (NVO) Denmark $377.087B 27.19
Johnson & Johnson (JNJ) United States $363.912B 15.13
AbbVie (ABBV) United States $309.709B 16.30
Merck (MRK) United States $248.613B 16.52
Roche Holding AG (RHHBY) Switzerland $247.847B 0.00
AstraZeneca (AZN) United Kingdom $217.852B 18.54
Novartis AG (NVS) Switzerland $210.389B 13.98
Pfizer (PFE) United States $150.855B 10.32
Sanofi (SNY) $132.349B 11.99
Bayer (BAYRY) Germany $22.242B 3.56